Literature DB >> 16870538

High throughput screening in drug discovery.

A Carnero1.   

Abstract

Drug discovery is a highly complex and multidisciplinary process which goal is to identify new antitumoral drugs. The screening attrition rate in the current drug discovery protocols suggests that one marketable drug emerges from approximately one million screened compounds. This leads to pressure to screen larger libraries in order to continue the pipeline and to the development of High Throughput Screening. HTS is only a name for specific developments in laboratory automation to collect a large amount of experimental data in a relatively short time. HTS can test hundreds of thousands of compounds per day, however, if fewer compounds could be tested without compromising the probability of success, the cost and time would be greatly reduced. To that end, new developments in large-scale cell biology and compound library design in silico have evolved to obtain data with higher predictability of clinical efficacy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16870538     DOI: 10.1007/s12094-006-0048-2

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  31 in total

1.  Diversity screening versus focussed screening in drug discovery.

Authors: 
Journal:  Drug Discov Today       Date:  2000-07       Impact factor: 7.851

2.  High throughput fluorescence polarization: a homogeneous alternative to radioligand binding for cell surface receptors.

Authors:  M Allen; J Reeves; G Mellor
Journal:  J Biomol Screen       Date:  2000-04

3.  An ultra-high throughput screening approach for an adenine transferase using fluorescence polarization.

Authors:  Z Li; S Mehdi; I Patel; J Kawooya; M Judkins; W Zhang; K Diener; A Lozada; D Dunnington
Journal:  J Biomol Screen       Date:  2000-02

4.  Fluorescent indicators for imaging protein phosphorylation in single living cells.

Authors:  Moritoshi Sato; Takeaki Ozawa; Kouichi Inukai; Tomoichiro Asano; Yoshio Umezawa
Journal:  Nat Biotechnol       Date:  2002-03       Impact factor: 54.908

5.  Akt/PKB localisation and 3' phosphoinositide generation at sites of epithelial cell-matrix and cell-cell interaction.

Authors:  S J Watton; J Downward
Journal:  Curr Biol       Date:  1999-04-22       Impact factor: 10.834

6.  The molecular structure of green fluorescent protein.

Authors:  F Yang; L G Moss; G N Phillips
Journal:  Nat Biotechnol       Date:  1996-10       Impact factor: 54.908

7.  A bioluminescence resonance energy transfer (BRET) system: application to interacting circadian clock proteins.

Authors:  Y Xu; D W Piston; C H Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

8.  Development of high throughput screening assays using fluorescence polarization: nuclear receptor-ligand-binding and kinase/phosphatase assays.

Authors:  G J Parker; T L Law; F J Lenoch; R E Bolger
Journal:  J Biomol Screen       Date:  2000-04

9.  Novel mutant green fluorescent protein protease substrates reveal the activation of specific caspases during apoptosis.

Authors:  N P Mahajan; D C Harrison-Shostak; J Michaux; B Herman
Journal:  Chem Biol       Date:  1999-06

10.  An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA.

Authors:  M L Zhang; C L Lorson; E J Androphy; J Zhou
Journal:  Gene Ther       Date:  2001-10       Impact factor: 5.250

View more
  23 in total

Review 1.  Bypassing cellular senescence by genetic screening tools.

Authors:  Mar Vergel; Amancio Carnero
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

2.  Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease.

Authors:  Wei Zheng; Janak Padia; Daniel J Urban; Ajit Jadhav; Ozlem Goker-Alpan; Anton Simeonov; Ehud Goldin; Douglas Auld; Mary E LaMarca; James Inglese; Christopher P Austin; Ellen Sidransky
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-01       Impact factor: 11.205

Review 3.  Adding more content to screening: reactivation of FOXO as a therapeutic strategy.

Authors:  Fabian Zanella; Amancio Carnero
Journal:  Clin Transl Oncol       Date:  2009-10       Impact factor: 3.405

4.  Re-engineering natural products to engage new biological targets.

Authors:  Stephen E Motika; Paul J Hergenrother
Journal:  Nat Prod Rep       Date:  2020-11-18       Impact factor: 13.423

5.  High-throughput screening assays to identify small molecules preventing photoreceptor degeneration caused by the rhodopsin P23H mutation.

Authors:  Yuanyuan Chen; Hong Tang
Journal:  Methods Mol Biol       Date:  2015

6.  Impact of Micellar Surfactant on Supersaturation and Insight into Solubilization Mechanisms in Supersaturated Solutions of Atazanavir.

Authors:  Anura S Indulkar; Huaping Mo; Yi Gao; Shweta A Raina; Geoff G Z Zhang; Lynne S Taylor
Journal:  Pharm Res       Date:  2017-03-28       Impact factor: 4.200

7.  Identification of Metabotropic Glutamate Receptor Subtype 5 Potentiators Using Virtual High-Throughput Screening.

Authors:  Ralf Mueller; Alice L Rodriguez; Eric S Dawson; Mariusz Butkiewicz; Thuy T Nguyen; Stephen Oleszkiewicz; Annalen Bleckmann; C David Weaver; Craig W Lindsley; P Jeffrey Conn; Jens Meiler
Journal:  ACS Chem Neurosci       Date:  2010-01-28       Impact factor: 4.418

Review 8.  Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines.

Authors:  Guangxu Jin; Stephen T C Wong
Journal:  Drug Discov Today       Date:  2013-11-14       Impact factor: 7.851

Review 9.  Matching the power of high throughput screening to the chemical diversity of natural products.

Authors:  Curtis J Henrich; John A Beutler
Journal:  Nat Prod Rep       Date:  2013-08-08       Impact factor: 13.423

10.  The XTT cell proliferation assay applied to cell layers embedded in three-dimensional matrix.

Authors:  Lynn Huyck; Christophe Ampe; Marleen Van Troys
Journal:  Assay Drug Dev Technol       Date:  2012-05-10       Impact factor: 1.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.